Incidence and risk of severe infections associated with anti-epidermal growth factor receptor monoclonal antibodies in cancer patients: a systematic review and meta-analysis

Table 2 Relative risk of severe infectious events with EGFR-MoAbs according to tumor types, EGFR-MoAbs, concomitant therapies and phases of trials

Groups	Studies, number	Severe infectious events, number/total, number		RR (95%CI)	Pvalue	Pvaluefor group difference
Groups	Studies, number	EGFR-MoAbs	Control	RR (95%CI)	Pvalue	Pvaluefor group difference
Tumor types
CRC	11	276/3801	181/3808	1.42 (1.05 to 1.93)	0.024	0.001
NSCLC	7	199/1341	137/1344	1.45 (1.19 to 1.77)	<0.001
Head and neck cancer	4	64/810	43/810	1.48 (1.02 to 2.13)	0.037
Others	4	62/494	77/397	0.72 (0.53 to 0.97)	0.033
Anti-EGFR MoAbs
Cetuximab	21	467/4548	299/4465	1.52 (1.33 to 1.75)	<0.001	0.092
Panitumumab	5	134/1898	139/1894	0.99 (0.62 to 1.60)	0.98	0.092
Concomitant therapies
Cisplatin	8	233/1690	148/1608	1.48 (1.22 to 1.79)	<0.001	0.30
Irinotecan	4	100/942	68/999	1.53 (1.12 to 2.10)	0.008
Oxaliplatin	8	192/2892	172/2847	0.97 (0.58 to 1.61)	0.90
Radiotherapy	3	13/312	11/313	0.99 (0.47 to 2.10)	0.98
Others	3	73/610	39/592	1.80 (1.24 to 2.62)	0.002
Phases of trials
Phase II	9	35/514	21/422	1.26 (0.75 to 2.12)	0.39	0.82
Phase III	17	566/5932	417/593	1.34 (1.08 to 1.67)	0.008	0.82
Overall	26	601/6446	438/6359	1.34 (1.10 to 1.62)	0.003	NA

CI, confidence interval; CRC, colorectal cancer; EGFR, epidermal growth factor receptor; MoAbs, monoclonal antibodies; NA, not available; NSCLC, non-small-cell lung cancer; RR, relative risk.

ISSN: 1741-7015